JP2018138578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018138578A5 JP2018138578A5 JP2018079985A JP2018079985A JP2018138578A5 JP 2018138578 A5 JP2018138578 A5 JP 2018138578A5 JP 2018079985 A JP2018079985 A JP 2018079985A JP 2018079985 A JP2018079985 A JP 2018079985A JP 2018138578 A5 JP2018138578 A5 JP 2018138578A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- concentration
- composition according
- insulin
- citrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 9
- 102000004877 Insulin Human genes 0.000 claims description 9
- 108090001061 Insulin Proteins 0.000 claims description 9
- 229940125396 insulin Drugs 0.000 claims description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 108010073961 Insulin Aspart Proteins 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 229960004717 insulin aspart Drugs 0.000 claims description 2
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical group CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 7
- 229920001993 poloxamer 188 Polymers 0.000 description 7
- 229940044519 poloxamer 188 Drugs 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 108010065920 Insulin Lispro Proteins 0.000 description 6
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 6
- 229960002068 insulin lispro Drugs 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 229940100630 metacresol Drugs 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101500025353 Homo sapiens Insulin A chain Proteins 0.000 description 1
- 101500025354 Homo sapiens Insulin B chain Proteins 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462092407P | 2014-12-16 | 2014-12-16 | |
| US62/092,407 | 2014-12-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531725A Division JP6328855B2 (ja) | 2014-12-16 | 2015-12-09 | 即効型インスリン組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020214703A Division JP7159277B2 (ja) | 2014-12-16 | 2020-12-24 | 即効型インスリン組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018138578A JP2018138578A (ja) | 2018-09-06 |
| JP2018138578A5 true JP2018138578A5 (enExample) | 2019-08-15 |
| JP7093669B2 JP7093669B2 (ja) | 2022-06-30 |
Family
ID=55066806
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531725A Active JP6328855B2 (ja) | 2014-12-16 | 2015-12-09 | 即効型インスリン組成物 |
| JP2018079985A Active JP7093669B2 (ja) | 2014-12-16 | 2018-04-18 | 即効型インスリン組成物 |
| JP2020214703A Active JP7159277B2 (ja) | 2014-12-16 | 2020-12-24 | 即効型インスリン組成物 |
| JP2022163910A Pending JP2023011641A (ja) | 2014-12-16 | 2022-10-12 | 即効型インスリン組成物 |
| JP2024199464A Pending JP2025032126A (ja) | 2014-12-16 | 2024-11-15 | 即効型インスリン組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531725A Active JP6328855B2 (ja) | 2014-12-16 | 2015-12-09 | 即効型インスリン組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020214703A Active JP7159277B2 (ja) | 2014-12-16 | 2020-12-24 | 即効型インスリン組成物 |
| JP2022163910A Pending JP2023011641A (ja) | 2014-12-16 | 2022-10-12 | 即効型インスリン組成物 |
| JP2024199464A Pending JP2025032126A (ja) | 2014-12-16 | 2024-11-15 | 即効型インスリン組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9993555B2 (enExample) |
| EP (2) | EP4108253A1 (enExample) |
| JP (5) | JP6328855B2 (enExample) |
| AR (1) | AR102869A1 (enExample) |
| CY (1) | CY1125275T1 (enExample) |
| DK (1) | DK3233108T3 (enExample) |
| ES (1) | ES2911207T3 (enExample) |
| HR (1) | HRP20220692T1 (enExample) |
| HU (1) | HUE058764T2 (enExample) |
| LT (1) | LT3233108T (enExample) |
| MA (1) | MA41188B1 (enExample) |
| MD (1) | MD3233108T2 (enExample) |
| PL (1) | PL3233108T3 (enExample) |
| PT (1) | PT3233108T (enExample) |
| RS (1) | RS63174B1 (enExample) |
| SI (1) | SI3233108T1 (enExample) |
| TW (1) | TW201630622A (enExample) |
| WO (1) | WO2016100042A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010009850A (es) | 2008-03-18 | 2010-09-30 | Novo Nordisk As | Analogos de insulina acilados y etabilizados contra proteasas. |
| KR20150082640A (ko) | 2012-11-13 | 2015-07-15 | 아도시아 | 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형 |
| TW201630622A (zh) * | 2014-12-16 | 2016-09-01 | 美國禮來大藥廠 | 速效胰島素組合物 |
| JO3749B1 (ar) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| AU2017334290B2 (en) * | 2016-09-29 | 2023-04-20 | Arecor Limited | Novel formulations |
| MA49116A (fr) | 2016-12-16 | 2020-03-25 | Novo Nordisk As | Compositions pharmaceutiques contenant de l'insuline |
| WO2018153506A1 (en) * | 2017-02-22 | 2018-08-30 | Adocia | Fast-acting insulin composition comprising a citric acid salt |
| WO2018182562A1 (en) * | 2017-03-26 | 2018-10-04 | Stafford Vivi Robyn | Method of treatment of skin conditions of eye lids |
| WO2018222787A1 (en) * | 2017-06-01 | 2018-12-06 | Eli Lilly And Company | Rapid-acting insulin compositions |
| WO2019193349A1 (en) | 2018-04-04 | 2019-10-10 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
| US20210113763A1 (en) * | 2018-04-04 | 2021-04-22 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
| IL277721B2 (en) | 2018-04-04 | 2024-03-01 | Arecor Ltd | Medical infusion pump system for the delivery of an insulin compound |
| WO2019243627A1 (fr) | 2018-06-23 | 2019-12-26 | Adocia | Dispositif pour injecter une solution d'insuline(s) |
| FR3083985A1 (fr) | 2018-07-23 | 2020-01-24 | Adocia | Dispositif pour injecter une solution d'insuline(s) |
| EP3937920B1 (en) * | 2019-03-14 | 2025-07-09 | The Regents of the University of California | Compositions comprising beta-hydroxybutyrate and citrate for supporting renal health |
| US10639328B1 (en) * | 2019-03-27 | 2020-05-05 | College Of William & Mary | Compositions and methods for reducing hyperglycemia and treating diabetes |
| US10799564B1 (en) | 2019-05-06 | 2020-10-13 | Baxter International Inc. | Insulin premix formulation and product, methods of preparing same, and methods of using same |
| WO2021055505A2 (en) * | 2019-09-17 | 2021-03-25 | Cass Pharmaceuticals, Inc. | Subcutaneously injectable insulin and glucagon formulations and methods of administration |
| KR20220115927A (ko) | 2019-10-25 | 2022-08-19 | 세르카코르 래버러토리즈, 인크. | 지표 화합물, 지표 화합물을 포함하는 장치, 및 이의 제조 및 사용 방법 |
| CA3170615A1 (en) * | 2020-03-02 | 2021-09-10 | Thermalin Inc. | Compositions containing rapid-acting insulin analogues |
| GB202004814D0 (en) | 2020-04-01 | 2020-05-13 | Arecor Ltd | Novel formulations |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK116527B (da) | 1967-03-01 | 1970-01-19 | Nordisk Insulinlab | Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse. |
| DE3064888D1 (en) | 1979-04-30 | 1983-10-27 | Hoechst Ag | Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization |
| FI78616C (fi) | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| US4839341A (en) * | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NO162160C (no) | 1987-01-09 | 1989-11-15 | Medi Cult As | Serumfritt vekstmedium, samt anvendelse derav. |
| WO1988006599A1 (en) | 1987-02-25 | 1988-09-07 | Novo Industri A/S | Novel insulin derivatives |
| US5716927A (en) | 1988-12-23 | 1998-02-10 | Novo Nordisk A/S | Insulin analogs having a modified B-chain |
| HUT56857A (en) | 1988-12-23 | 1991-10-28 | Novo Nordisk As | Human insulin analogues |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| AUPO066096A0 (en) | 1996-06-26 | 1996-07-18 | Peptide Delivery Systems Pty Ltd | Oral delivery of peptides |
| EP1044016B1 (en) | 1998-01-09 | 2005-03-16 | Novo Nordisk A/S | Stabilised insulin compositions |
| ES2180511T3 (es) | 1999-01-26 | 2003-02-16 | Lilly Co Eli | Formulaciones monodispersas de analogos de insulina acilados hexamericos. |
| JP2003514014A (ja) | 1999-11-15 | 2003-04-15 | ティー ガンガル，ハナマラディ | 静脈注入のためのブドウ糖およびインスリン含有液体配合物 |
| JP4147234B2 (ja) | 2004-09-27 | 2008-09-10 | キヤノン株式会社 | 吐出用液体、吐出方法、カートリッジ及び吐出装置 |
| US20020141946A1 (en) | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| WO2005046716A1 (en) * | 2003-11-13 | 2005-05-26 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| EP2106790B1 (en) | 2004-03-12 | 2012-10-24 | Biodel, Inc. | Rapid acting drug delivery compositions |
| WO2007041481A1 (en) | 2005-09-29 | 2007-04-12 | Biodel, Inc. | Rapid acting and prolonged acting insulin preparations |
| US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US7713929B2 (en) * | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| CA2649109A1 (en) | 2006-04-12 | 2007-10-25 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| US8084022B2 (en) | 2006-06-23 | 2011-12-27 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2008013955A2 (en) | 2006-07-27 | 2008-01-31 | Nektar Therapeutics | Sustained release formulations for pulmonary delivery |
| WO2008152106A1 (en) | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
| EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| US20120094902A1 (en) | 2009-03-27 | 2012-04-19 | Adocia | Fast-acting insulin formulation |
| FR2943538B1 (fr) | 2009-03-27 | 2011-05-20 | Adocia | Formulation a action rapide d'insuline recombinante humaine |
| KR101775000B1 (ko) | 2009-06-26 | 2017-09-04 | 노보 노르디스크 에이/에스 | 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제 |
| US20120178675A1 (en) | 2010-07-07 | 2012-07-12 | Biodel Inc. | Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin |
| CN105797140B (zh) | 2011-06-17 | 2020-08-11 | 哈洛齐梅公司 | 乙酰透明质酸降解酶的稳定制剂 |
| US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| BR112013032265A2 (pt) | 2011-06-17 | 2016-12-20 | Halozyme Inc | métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano |
| US20130231281A1 (en) | 2011-11-02 | 2013-09-05 | Adocia | Rapid acting insulin formulation comprising an oligosaccharide |
| BR112014016195A2 (pt) | 2011-12-30 | 2020-10-27 | Halozyme, Inc. | variantes de polipeptídio ph20, formulações e usos das mesmas |
| US9381247B2 (en) | 2012-04-16 | 2016-07-05 | Biodel Inc. | Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain |
| US9399065B2 (en) | 2012-04-16 | 2016-07-26 | Biodel Inc. | Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin |
| US20150174209A1 (en) | 2012-05-25 | 2015-06-25 | Amylin Pharmaceuticals. Llc | Insulin-pramlintide compositions and methods for making and using them |
| KR20150082640A (ko) * | 2012-11-13 | 2015-07-15 | 아도시아 | 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형 |
| US20150065423A1 (en) | 2013-08-30 | 2015-03-05 | Perosphere, Inc. | Rapid acting injectable formulations |
| WO2015106269A2 (en) | 2014-01-13 | 2015-07-16 | Thermalin Diabetes, Llc | Rapid action insulin formulations and pharmaceutical delivery systems |
| WO2015120457A1 (en) | 2014-02-10 | 2015-08-13 | Biodel Inc. | Stabilized ultra-rapid-acting insulin formulations |
| US9795678B2 (en) | 2014-05-14 | 2017-10-24 | Adocia | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound |
| TW201630622A (zh) * | 2014-12-16 | 2016-09-01 | 美國禮來大藥廠 | 速效胰島素組合物 |
| JO3749B1 (ar) * | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
-
2015
- 2015-12-01 TW TW104140209A patent/TW201630622A/zh unknown
- 2015-12-01 AR ARP150103921A patent/AR102869A1/es unknown
- 2015-12-09 ES ES15817678T patent/ES2911207T3/es active Active
- 2015-12-09 DK DK15817678.4T patent/DK3233108T3/da active
- 2015-12-09 MD MDE20170200T patent/MD3233108T2/ro unknown
- 2015-12-09 SI SI201531823T patent/SI3233108T1/sl unknown
- 2015-12-09 WO PCT/US2015/064744 patent/WO2016100042A1/en not_active Ceased
- 2015-12-09 RS RS20220416A patent/RS63174B1/sr unknown
- 2015-12-09 LT LTEPPCT/US2015/064744T patent/LT3233108T/lt unknown
- 2015-12-09 HR HRP20220692TT patent/HRP20220692T1/hr unknown
- 2015-12-09 JP JP2017531725A patent/JP6328855B2/ja active Active
- 2015-12-09 PT PT158176784T patent/PT3233108T/pt unknown
- 2015-12-09 EP EP22164140.0A patent/EP4108253A1/en active Pending
- 2015-12-09 PL PL15817678T patent/PL3233108T3/pl unknown
- 2015-12-09 HU HUE15817678A patent/HUE058764T2/hu unknown
- 2015-12-09 EP EP15817678.4A patent/EP3233108B1/en active Active
- 2015-12-09 US US14/963,279 patent/US9993555B2/en active Active
- 2015-12-09 MA MA41188A patent/MA41188B1/fr unknown
-
2018
- 2018-04-18 JP JP2018079985A patent/JP7093669B2/ja active Active
- 2018-05-14 US US15/978,329 patent/US11123406B2/en active Active
-
2020
- 2020-12-24 JP JP2020214703A patent/JP7159277B2/ja active Active
-
2021
- 2021-09-17 US US17/478,747 patent/US11872266B2/en active Active
-
2022
- 2022-05-11 CY CY20221100329T patent/CY1125275T1/el unknown
- 2022-10-12 JP JP2022163910A patent/JP2023011641A/ja active Pending
-
2023
- 2023-12-14 US US18/540,193 patent/US20240238382A1/en active Pending
-
2024
- 2024-11-15 JP JP2024199464A patent/JP2025032126A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018138578A5 (enExample) | ||
| JP7159277B2 (ja) | 即効型インスリン組成物 | |
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| JP6835831B2 (ja) | 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法 | |
| KR102327754B1 (ko) | 안정한 펩티드 제형물 및 제조 방법 | |
| MX2014012245A (es) | Composiciones de magnesio para modular la farmacocinetica y farmacodinamica de insulina y analogos de insulina, y el dolor en el sitio de inyeccion. | |
| JP2012096063A (ja) | 医薬容器内の安定化した液体タンパク質の処方物 | |
| JP2010530846A (ja) | 高温で安定なペプチド製剤 | |
| JP2016539921A5 (enExample) | ||
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| CA2295140A1 (en) | Stable insulin formulations | |
| CZ234898A3 (cs) | Zdokonalené koncentrované injekční a infusní roztoky pro intravazální použití | |
| HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
| CN107949374A (zh) | 稳定的胰高血糖素溶液 | |
| JP2023166014A (ja) | コラーゲン７組成物及びそれを用いる方法 | |
| CN107106659B (zh) | 肠胃外胰高血糖素制剂 | |
| US20170312297A1 (en) | Long Acting Pharmaceutical Compositions For Hepatitis C | |
| PE20252784A1 (es) | Composiciones y metodos para administrar paltusotina a pacientes con insuficiencia hepatica | |
| JPWO2023086980A5 (enExample) | ||
| IL312623A (en) | Preserved formulations | |
| RU2020109402A (ru) | Композиции на основе glp-1 и пути их применения | |
| HK40070081B (zh) | 非质子极性溶剂中的稳定治疗组合物及其制造方法 | |
| CN110201148A (zh) | Prrt4细胞因子在制备治疗肝功能衰竭药剂中的应用 | |
| WO2003043537A1 (en) | Improvements in curing aids with tetrasilver tetroxide molecular crystal devices |